Castle Biosciences (NASDAQ: CSTL) CEO sells 4,172 shares via trusts

Castle Biosciences CEO Derek Maetzold sold a total of 4,172 shares of common stock at a weighted-average price of $25.098 per share on April 21, 2026, as part of a pre-arranged Rule 10b5-1 trading plan. Concurrently, Maetzold exercised stock options to acquire 550 shares at $2.39 per share, selling a matching number of shares. After these transactions, Maetzold directly holds 21,479 shares, with additional indirect holdings through various family trusts.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.
  • Reward
  • Comment
  • Repost
  • Share
Comment
Add a comment
Add a comment
No comments
  • Pin